Elixiron Immunotherapeutics (Cayman) Limited (TPEX:7871)

Market Cap	9.47B
Revenue (ttm)	1.03M -96.9%
Net Income	-1.36B
EPS	-57.45
Shares Out	134.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	659,236
Average Volume	890,811
Open	71.30
Previous Close	71.00
Day's Range	69.50 - 72.00
52-Week Range	37.55 - 92.20
Beta	n/a
RSI	43.32
Earnings Date	n/a

About TPEX:7871

Elixiron Immunotherapeutics (Cayman) Limited engages in the development of precision-targeted immunotherapy drugs in Shanghai, Taipei, the United States and Switzerland. It develops EI-1071, a small molecule inhibitor of CSF-1R used for the treatment of Alzheimer's disease and amyotrophic lateral sclerosis; EI-001 for the treatment of vitiligo and Hemophagocytic Lymphohistiocytosis (HLH); and EI-012, a monoclonal antibody and EI-220 mRNA for the treatment of cancer. Elixiron Immunotherapeutics (Cayman) Limited was incorporated in 2017 and is he...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7871